CureVac N.V. risk profile
11 Contained slack in every measured input
Measured 1 September 2026 from CVAC's filed statements. Recomputed nightly.
11 (Contained), driven by Cash conversion at 34, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 33 | Normal | Stable | One-year price volatility — 28.8% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -886.5 percentage points |
| Cash conversion | 34 | Normal | Easing | Cash conversion — 0.63x |
| Leverage and coverage | 0 | Contained | Easing | Net debt to EBITDA — -2.11x |
| Competitive position | 10 | Contained | Stable | R&D-intensity gap against peers — +0.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.